Carlos Fabián Amigo Mendoza, Luiz Claudio Santos Thuler, Eloá Moreira-Marconi, Suzana Sales de Aguiar, Ivana Leao Ribeiro, Anke Bergmann
{"title":"Factors associated with early death among children and adolescents with cancer in Brazil: a nationwide registry-based study.","authors":"Carlos Fabián Amigo Mendoza, Luiz Claudio Santos Thuler, Eloá Moreira-Marconi, Suzana Sales de Aguiar, Ivana Leao Ribeiro, Anke Bergmann","doi":"10.1080/08880018.2026.2733752","DOIUrl":null,"url":null,"abstract":"<p><p>This study aimed to identify sociodemographic, clinical, and care-related factors associated with early death in childhood and adolescent cancer patients in Brazil. A retrospective cohort study was conducted using data from the Brazilian Hospital Cancer Registry Integrator Database (IntegradorRHC). All cancer cases diagnosed in individuals aged 0-19 years between 2000 and 2023 were included. Early death was defined as death at the end of the first treatment or within 12 months after diagnosis. Associations were assessed using multivariable logistic regression, and results were expressed as adjusted odds ratios (aOR) with 95% confidence intervals (CI). Among 102,430 eligible cases, early death occurred in 24.7%. Increased risk of early death was independently associated with older age at diagnosis (aOR = 1.006), non-white race/skin color (aOR = 1.467), missing information on race/skin color (aOR = 3.177), unknown referral origin (aOR = 3.507), residence in the Southeast region (aOR = 1.921), and receipt of chemotherapy (aOR = 1.624). Central nervous system tumors (aOR = 2.430), soft tissue sarcomas, bone tumors, and leukemias showed the highest risk of early death. Surgery (aOR = 0.636) and radiotherapy (aOR = 0.750) were associated with reduced risk, while lymphomas (aOR =0.70) showed a protective association. Early death among pediatric cancer patients in Brazil is strongly influenced by tumor type and marked social, regional, and informational disparities.</p>","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":" ","pages":"429-444"},"PeriodicalIF":1.4000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Hematology and Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08880018.2026.2733752","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/9/16 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
This study aimed to identify sociodemographic, clinical, and care-related factors associated with early death in childhood and adolescent cancer patients in Brazil. A retrospective cohort study was conducted using data from the Brazilian Hospital Cancer Registry Integrator Database (IntegradorRHC). All cancer cases diagnosed in individuals aged 0-19 years between 2000 and 2023 were included. Early death was defined as death at the end of the first treatment or within 12 months after diagnosis. Associations were assessed using multivariable logistic regression, and results were expressed as adjusted odds ratios (aOR) with 95% confidence intervals (CI). Among 102,430 eligible cases, early death occurred in 24.7%. Increased risk of early death was independently associated with older age at diagnosis (aOR = 1.006), non-white race/skin color (aOR = 1.467), missing information on race/skin color (aOR = 3.177), unknown referral origin (aOR = 3.507), residence in the Southeast region (aOR = 1.921), and receipt of chemotherapy (aOR = 1.624). Central nervous system tumors (aOR = 2.430), soft tissue sarcomas, bone tumors, and leukemias showed the highest risk of early death. Surgery (aOR = 0.636) and radiotherapy (aOR = 0.750) were associated with reduced risk, while lymphomas (aOR =0.70) showed a protective association. Early death among pediatric cancer patients in Brazil is strongly influenced by tumor type and marked social, regional, and informational disparities.
期刊介绍:
PHO: Pediatric Hematology and Oncology covers all aspects of research and patient management within the area of blood disorders and malignant diseases of childhood. Our goal is to make PHO: Pediatric Hematology and Oncology the premier journal for the international community of clinicians and scientists who together aim to define optimal therapeutic strategies for children and young adults with cancer and blood disorders. The journal supports articles that address research in diverse clinical settings, exceptional case studies/series that add novel insights into pathogenesis and/or clinical care, and reviews highlighting discoveries and challenges emerging from consortia and conferences. Clinical studies as well as basic and translational research reports regarding cancer pathogenesis, genetics, molecular diagnostics, pharmacology, stem cells, molecular targeting, cellular and immune therapies and transplantation are of interest. Papers with a focus on supportive care, late effects and on related ethical, legal, psychological, social, cultural, or historical aspects of these fields are also appreciated. Reviews on important developments in the field are welcome. Articles from scientists and clinicians across the international community of Pediatric Hematology and Oncology are considered for publication. The journal is not dependent on or connected with any organization or society. All submissions undergo rigorous peer review prior to publication. Our Editorial Board includes experts in Pediatric Hematology and Oncology representing a wide range of academic and geographic diversity.